Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024591 (malignant hyperthermia)
 2,353 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 53 year old obese male presented with the signs and symptoms of acute appendicitis and a family history suggesting the possibility of a malignant hyperthermia trait. In spite of spinal anaesthesia the patient developed malignant hyperthermia during the appendicectomy and the attack was successfully aborted with the early use of dantrolene sodium (Dantrium, Norwich Eaton).
 ...
PMID:Malignant hyperthermia and the conscious patient. 317 98

Malignant hyperpyrexia (MH) is a syndrome with a mortality of 60%, triggered by a broad variety of anesthetic agents. The most significant recent advance influencing the clinician's ability to safely manage MH individuals is the emergence of dantrolene sodium as both a prophylactic and a therapeutic agent. The purpose of this presentation is to review recent clinical and laboratory studies and advances which are the basis for establishing the pathophysiology of this syndrome and pharmacology of treatment. The FDA has recently approve intravenous Dantrium for treatment of malignant hyperpyrexia. Intravenous and oral Dantrium has much theoretical support and experimental evidence which suggests it will significantly reduce the mortality previously associated with this syndrome.
 ...
PMID:Malignant hyperpyrexia: an update for the otolaryngologist. 724 87

The pharmacogenetic syndrome of malignant hyperthermia (MH) in response to general anaesthesia, though rare, is usually fatal when it does occur. A case of anaesthetic-induced MH arising in a 10-year-old girl during intranasal antrostomy and successfully treated with dantrolene sodium (Dantrium; SKF) is described. A treatment protocol for MH is appended. The importance of an awareness on the part of the clinician together with prompt reaction to early tell-tale signs is stressed.
 ...
PMID:Dantrolene sodium in the treatment of malignant hyperthermia. A case report. 730 73

Dantrolene effectively treats malignant hyperthermia (MH) hut the current form, Dantrium, must be dissolved to a 0.33 mg/mL, pH 9.5 solution. This study describes lecithin-coated microcrystal formulations of sodium dantrolene (MC-NaD) and neutral dantrolene (MC-D) which reconstitute to 200 mg/mL within 1 min. In rats, the pharmacokinetics and pharmacodynamics of MC-NaD and Dantrium were similar: half-lives of 3.1 h, volume distributions of 0.54 and 0.59 L/kg, and 95% effective dose (ED95) values for depression of skeletal muscle twitch height (ED95T) of 2.6 +/- 0.7 and 2.8 +/- 0.5 mg/kg. In swine, the ED95T values for MC-NaD and Dantrium were also similar (2.8 +/- 0.4 vs 2.7 +/- 0.6 mg/kg), but MC-D and Dantrium were only similar at doses more than 2.5 mg/kg (ED95T: 3.5 +/- 0.4 vs 2.7 +/- 0.5 mg/kg). In susceptible swine, MC-NaD successfully treated five of six MH episodes and prevented MH in three of four swine. However, MC-NaD caused marked pulmonary hypertension in swine, while MC-D caused only a mild response that was eliminated by filtration. Likewise, MC-D caused no pulmonary response in dogs. These observations suggest that MC-D has potential to improve the treatment of MH.
 ...
PMID:Intravenous lecithin-coated microcrystals of dantrolene are effective in the treatment of malignant hyperthermia: an investigation in rats, dogs, and swine. 861

The administration of intravenous dantrolene in a parturient susceptible to malignant hyperthermia has been associated with post partum uterine atony. We examined the effect of dantrolene sodium for injection (Dantrium Intravenous) on spontaneous contractility of uterine smooth muscle from women in term pregnancy in an isolated preparation. Dantrolene sodium for injection at 5 microg/ml and 10 microg/ml had no effect on the spontaneous contractility of the uterine muscle preparations. At a cumulative concentration of 20 microg/ml, a mild depression (16 +/- 14%) in the frequency of spontaneous contractions was noted. However, a similar depression in the muscle preparations treated with mannitol suggests that the depression observed with the dantrolene was likely due to the mannitol that was included in the dantrolene formulation rather than to dantrolene sodium itself. We conclude that dantrolene sodium has no effect on the spontaneous contractility of uterine smooth muscle. The depression of uterine muscle activity observed with dantrolene for injection appears attributable to the mannitol.
 ...
PMID:Effect of dantrolene sodium on contractility of isolated human uterine muscle. 1563 10